Ranbaxy gets 180 days of exclusivity for generic Aricept

09/21/2010 | Bloomberg

Ranbaxy Laboratories gained exclusive rights to sell a generic version of Eisai's Alzheimer's drug Aricept. The FDA said Teva Pharmaceutical Industries, which has approval to sell the drug, must wait 180 days before competing with Ranbaxy.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA
Actuary
NTA Life
Addison, TX
Chief Information Officer
Meridian Health Plan
Detroit, MI
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA